BioSpace News Archive

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of additional endpoints from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer.

Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., announced that positive interim results from a Phase 2a trial of its investigational novel gene therapy, URO-902, were presented Friday at the 2022 annual meeting of the American Urological Association (AUA2022).

AESARA (www.aesara.com) is pleased to announce their attendance and poster presentations this ISPOR 2022 held in Washington, D.C. from May 16 – 18, 2022.

Vytal, a pharmacy service and healthcare technology company, today announced the appointment of Prasanna Parthasarathy as chief executive officer.

Men who take Viagra, Cialis or Levitra and other drugs of the same class for erectile dysfunction (ED) experience lower rates of heart failure and death due to heart disease compared to other men, according to a study presented on May 13 at scientific meetings of the American Heart Association in Reston, Virginia.

Olympus announced that its iTind™ procedure for the treatment of enlarged prostate won Gold in the 2022 Medical Design Excellence Awards and Silver in the 2022 Edison Awards.

Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that Health Canada has accepted the filing of a Supplement to a New Drug Submission for an investigational oral formulation of edaravone indicated for the treatment of amyotrophic lateral sclerosis.

Brain Scientific (OTCQB:BRSF) today reports its business highlights and financial results for the first quarter ended March 31, 2022.

Following the launch of QUVIVIQ™ CIV on May 2, Idorsia Pharmaceuticals, U.S. Inc. announced that the first wave of patients has been prescribed the product through a pharmacy services provider.

Today, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.